All In Biotech

Drug Trial Radar · NCT07801222

A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma

A First-in-human Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma and Soft Tissue Sarcoma

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Jan 19, 2029

Study completion May 21, 2030

Sponsor

Lead sponsor
SOTIO Biotech a.s.Industry
Sponsor type
Industry
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SOT106 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called LRRC15, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT106, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.

Conditions

  • Osteosarcoma Metastatic
  • Soft Tissue Sarcoma (STS)
  • Osteosarcoma, Advanced

Interventions

  • SOT106Biological

    SOT106 is a LRRC15-directed monoclonal antibody conjugated to a linker-payload, Monomethyl auristatin E

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT106Time frame: At the end of Cycle 1 (one cycle is 21 days)
  2. Part B: Optimal dose of SOT106 for subsequent clinical trialsTime frame: Cycle 1 Day 1 up to 30 days after the last dose (each cycle is 21 days)
  3. Part B: Objective Response Rate (ORR) of SOT106Time frame: From Day 1 of Cycle 1 (one cycle is 21 days) until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, to be assessed up to approximately 10 months
  4. Part B: Duration of Response (DoR) of SOT106Time frame: From the date of first documented objective response until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, assessed up to approximately 10 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Arensia Exploratory Medicine Research Unit, Institute of Oncology

    Chisinau, Moldova

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.